UNSPSC 51292918: Desipramine trifluoroacetate

This classification denotes a tricyclic antidepressant with the molecular formula C18H22N2.C2HF3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5T6XJJ77M3, chemically known as acetic acid, trifluoro-, compd. with 10,11-dihydro-n-methyl-5h-dibenz(b,f)azepine-5-propanamine (1:1), but more generally known as desipramine trifluoroacetate, which bears US NIH Compound Identifier 151119.

European Medicines Agency schedules desipramine trifluoroacetate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06995MIG. Most nations, for tariff purposes, schedule desipramine trifluoroacetate under HS 29339990. SMILES: CNCCCN1C2CCCCC2CCC3C1CCCC3.C(=O)(C(F)(F)F)O.

UNSPSC 51292918 Desipramine trifluoroacetate, a Commodity code, shows minimal recent state and local procurement activity under its nominal scope. The single identified opportunity does not align with the code's pharmaceutical designation—Seminole County, Florida posted an IFB for naloxone and drug deactivation systems, products unrelated to desipramine trifluoroacetate. The mismatch suggests that either the opportunity was misclassified at posting or the code reflects a narrow pharmaceutical compound with limited state and local procurement demand. State and local governments do not appear to be actively soliciting desipramine trifluoroacetate at present based on recent posting records.

The one recorded activity is Seminole County's IFB 60459723LAS, posted June 30, 2026, with response deadline July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract includes a two-year initial term with one-year renewal option and was potentially funded through FEMA. Beyond this single Florida county opportunity, no geographic spread or representative activity supporting the desipramine trifluoroacetate code itself is present in the source material. The code warrants close monitoring for actual pharmaceutical procurement demand aligned to its scope, as current activity suggests it may not be a reliable signal for business development targeting state and local markets.